MENU
SNY
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SNY stock forecast, quote, news & analysis

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases... Show more

SNY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SNY with price predictions
Jul 09, 2026

Momentum Indicator for SNY turns positive, indicating new upward trend

SNY saw its Momentum Indicator move above the 0 level on July 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SNY just turned positive on July 02, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

SNY moved above its 50-day moving average on July 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for SNY crossed bearishly below the 50-day moving average on June 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.267) is normal, around the industry mean (19.876). P/E Ratio (19.469) is within average values for comparable stocks, (28.140). Projected Growth (PEG Ratio) (3.875) is also within normal values, averaging (3.922). SNY has a moderately high Dividend Yield (0.055) as compared to the industry average of (0.031). P/S Ratio (1.975) is also within normal values, averaging (4.230).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.

A.I.Advisor
published Dividends

SNY paid dividends on June 03, 2026

Sanofi ADS SNY Stock Dividends
А dividend of $2.42 per share was paid with a record date of June 03, 2026, and an ex-dividend date of May 04, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 196.55B. The market cap for tickers in the group ranges from 72.83K to 1.09T. LLY holds the highest valuation in this group at 1.09T. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 7%. SCLX experienced the highest price growth at 18%, while NSRX experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was -31% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 60
Price Growth Rating: 42
SMR Rating: 52
Profit Risk Rating: 63
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
SNY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a producer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
46, Avenue de la Great Army
Phone
+33 153774000
Employees
74846
Web
https://www.sanofi.com
Momentum Indicator for SNY turns positive, indicating new upward trend